Brammer is a sponsor and will participate in the MassBio Forum event in Boston, MA.
| CAMBRIDGE, Mass., Feb. 28, 2019 /PRNewswire/ -- Brammer Bio (“Brammer”), a best-in-class viral vector contract development and manufacturing organization (CDMO) for cell and gene therapy companies, supports Rare Disease Day in raising awareness about rare diseases and their impact on patients’ lives.
Rare Disease Day, held on the last day of February each year, is inspired to encourage our policy makers, public authorities, industry colleagues, researchers, and health professionals in efforts to address the unmet medical needs of patients with rare diseases. For more information, please visit www.rarediseaseday.org. Brammer is a sponsor and will participate in the MassBio Forum event in Boston, MA. Mark Bamforth, CEO of Brammer, commented, “One in 20 people will live with a rare disease at some point in their life, and an increasing number of gene therapy companies are targeting rare diseases, and some of these treatments are demonstrating outstanding safety and efficacy,” said Bamforth.” The Brammer team consists of 600 extraordinary employees who are focused exclusively on developing processes and suppling products to meet the gene therapy needs of our clients and their patients.” Brammer offers end-to-end CDMO services from clinical supply in Florida through commercial manufacturing at two sites in Massachusetts. At its Alachua, Fla. facilities, Brammer is building on a 13+ year track record of supplying first-in-human clinical materials by expanding its process and analytical development laboratories and quality control laboratories and warehousing in early 2019. Brammer is conducting a further expansion of its first commercial facility, located in Cambridge, Mass., increasing the number of commercial suites, supporting up to 2,000-liter suspension and large-scale adherent processes. Construction of this additional capacity will be completed in the first half of 2019. In Lexington, Mass., Brammer is renovating a 50,000-square foot facility as its second commercial facility for adherent processes using the Pall iCELLis® 500 platform and Pall Allegro™ STR Single-use Stirred Tank Bioreactors. Construction will be completed in mid-2019. About Brammer Bio About Ampersand Capital Partners
SOURCE Brammer Bio |
View original content to download multimedia:
